ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ALLR Allarity Therapeutics Inc

1.22
-0.01 (-0.81%)
プレマーケット
最終更新日: 17:54:59
15分遅延
名称 銘柄コード 市場 種別
Allarity Therapeutics Inc ALLR NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.01 -0.81% 1.22 17:54:59
始値 安値 高値 終値 前日終値
1.23
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/0221:00GLOBEAllarity Therapeutics’ Stenoparib Shows Clear Clinical..
2024/4/2920:00GLOBEAllarity Therapeutics Regains Compliance with NASDAQ Minimum..
2024/4/1722:10GLOBEAllarity Therapeutics Receives NASDAQ-Approved Extension to..
2024/4/0422:15GLOBEAllarity Therapeutics Announces 1-for-20 Reverse Stock Split
2024/3/2721:30GLOBEAllarity Therapeutics Makes Strategic Pivot to Focus Solely..
2024/3/2520:30GLOBEAllarity Therapeutics Receives Extension from Nasdaq..
2024/3/0822:38EDGAR2Form 8-K - Current report
2024/3/0821:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/3/0821:15GLOBEAllarity Therapeutics Reports Full Year 2023 Financial..
2024/3/0811:45EDGAR2Form DEF 14A - Other definitive proxy statements
2024/3/0506:05EDGAR2Form 8-K - Current report
2024/3/0123:21EDGAR2Form 8-K - Current report
2024/2/2820:00GLOBEAllarity Therapeutics to Present at Biomarkers 2024
2024/2/2406:09EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
2024/2/1423:03EDGAR2Form 8-K - Current report
2024/2/0307:03EDGAR2Form D - Notice of Exempt Offering of Securities
2024/2/0206:40EDGAR2Form 8-K - Current report
2024/1/2707:07EDGAR2Form PRE 14A - Other preliminary proxy statements
2024/1/2607:24EDGAR2Form 8-K - Current report
2024/1/2007:29EDGAR2Form 8-K - Current report
2023/12/1607:00EDGAR2Form S-1/A - General form for registration of securities..
2023/12/1220:00GLOBEAllarity Therapeutics Announces Thomas Jensen as Interim CEO..
2023/12/1120:30EDGAR2Form 8-K - Current report
2023/12/0707:00EDGAR2Form 8-K - Current report
2023/12/0622:30EDGAR2Form S-1/A - General form for registration of securities..
2023/12/0521:30EDGAR2Form 8-K - Current report
2023/12/0521:30GLOBEAllarity’s Early Phase 2 Stenoparib Data Indicates Clinical..
2023/11/1807:01EDGAR2Form 8-K - Current report
2023/11/1322:35EDGAR2Form 8-K - Current report
2023/11/0306:00EDGAR2Form S-3 - Registration statement under Securities Act of..
2023/10/3122:30EDGAR2Form S-1 - General form for registration of securities under..
2023/10/3106:00EDGAR2Form 8-K - Current report
2023/10/2406:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2023/10/1806:00EDGAR2Form S-3/A - Registration statement under Securities Act of..
2023/10/1106:00EDGAR2Form S-3 - Registration statement under Securities Act of..
2023/10/0220:00GLOBEAllarity Therapeutics to Present at Biomarkers Europe 2023
2023/9/2805:30EDGAR2Form 8-K - Current report
2023/9/1521:45EDGAR2Form 8-K - Current report
2023/8/3105:05GLOBEPLOS ONE Publishes Data on Allarity Therapeutics’ DRP®..
2023/8/1504:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/1121:15EDGAR2Form 8-K - Current report
2023/7/3119:00GLOBEAllarity Therapeutics and FivepHusion Announce Collaboration..
2023/7/2805:01EDGAR2Form 8-K - Current report
2023/7/2419:00GLOBEAllarity Therapeutics Strengthens Board of Directors with..
2023/7/1806:10EDGAR2Form 8-K - Current report
2023/7/1205:05EDGAR2Form 8-K - Current report
2023/7/0805:30EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
2023/7/0619:05EDGAR2Form 8-K - Current report
2023/7/0619:00GLOBEAllarity Therapeutics, Inc. Announces Pricing of $11 Million..
2023/7/0605:31EDGAR2Form 8-K - Current report

最近閲覧した銘柄

Delayed Upgrade Clock